BORDERLINE OVARIAN CANCER | aqorn learning | @rahat2021 | FCPS | MCPS | MRCOG | TOACS |
HTML-код
- Опубликовано: 11 сен 2024
- @rahat2021
Borderline ovarian tumors, initially described as semi-malignant by Taylor in 1929, were officially classified by the International Federation of Gynecology and Obstetrics and the World Health Organization in 1970. There are two primary subtypes: serous and mucinous, with serous tumors being more common and believed to originate from the germinal epithelium, while mucinous tumors are thought to originate from the appendix.
The exact cause of this disease remains unclear due to limited cases and research, but there may be links to factors like oral contraceptive use, age at first pregnancy, menstrual history, smoking, and family history of ovarian cancer. In the United States, 1.8% of women will develop some form of ovarian cancer in their lifetime, with borderline ovarian tumors classified as benign.
Most patients (around 75%) are diagnosed at an early stage, with staging based on the FIGO classification of ovarian cancer. The prognosis for stage I patients is excellent, with a 5-year survival rate approaching 100%. Stage II-IV patients have a different prognosis, with increased stage associated with a worse outcome.
Fertility-sparing surgery is considered for stage I patients, with no statistical difference in recurrence found between surgical approaches. Patients attempting pregnancy after such surgery have achieved a 50% conception rate. Diagnostic tools include cancer antigen 125, transvaginal color Doppler ultrasonography, and computed tomography scanning.
Treatment involves surgical tumor removal and biopsies, but postoperative management remains uncertain. Various chemotherapy regimens have been explored, but evidence is insufficient to determine the best approach. Hysterectomy and oophorectomy may be avoided for patients wishing to preserve fertility, with comprehensive staging being essential. Overall, complications mostly arise from surgery, therapy, or recurrence.
• Playlist
RUclips channel
/ @rahatq2021
Hi, This RUclips channel has been created to help postgraduate trainees in Obstetrics and Gynecology learn and develop clinical skills for history taking, communication, counselling, quality assurance, critical reading of the literature.
Great video, thank you
Glad you liked it!
Great video, so little available on this topic. I’ve had my ovary and fallopian tube removed. There was no abnormal cells in ovary or tube, the serous tumour was contained inside the cyst and removed wholly. A peritoneal wash was done and no abnormal cells found. They’ve done further tests on the tumour and have just told me it was on the cusp of malignancy. So on the spectrum of borderline, it was much closer to malignant. I want to watch and wait, and hope for no recurrence. I’m getting CT scan soon and seeing an oncologist. Because my tumour was closer to malignant, does it mean it’s more advanced in stage? My surgeon said you can’t stage properly unless you remove everything. But I’m thinking if no cells have been found outside of the tumour, shouldn’t that be a good indicator?
glad you appreciated the video. let me know if you want a video on another topic. i try to make videos on topics which are not clearly in the textbooks or guidelines.
Nice, feeling how the bloating and pain receded within approximately two months made all the difference, I simply go’ogled the latest by Tilly Strankten and her Ovarian Cyst Guide and although it really took about 10 weeks for it to totally shrink and vanish I’ve never felt so light and relaxed.
I had serous epithelial borderline tumor in right ovary. Now I have open surgery opharectomy.
I am 37 years . Dr give me 2 option , I: remove the whole system or go on 3 month follow up .please suggest what is best option
if you have already had the surgery for the borderline tumor and if you are not high risk for ovarian cancer then you can go for follow up and retain your reproduction ability.
@@rahatq2021 yes I had my surgery already .but how I know that I am on high risk or not ?